Chlamydia Insights and Trends

• According to World Health Organization, in 2020 there were an estimated 128.5 million new chlamydia infections among adults globally.
• As per European Centre for Disease Prevention and Control, for 2023, 230,199 confirmed cases of chlamydia infection were reported in 27 EU/EEA countries.
• To reduce the risks, screening for chlamydia is implemented in several countries and regions, including the US and the UK. Screening is recommended for all women younger than 25 years, pregnant women, and women at increased risk of infection. 
• Diagnosis of chlamydia trachomatis infection is most commonly confirmed using nucleic acid amplification tests, which detect bacterial genetic material from urine or genital swab samples with high accuracy.

Chlamydia Epidemiology Forecast in the 7MM

• 2025 Chlamydia Incident Cases: XXX
• 2036 Projected Chlamydia Incident Cases: XXX
• Chlamydia Growth Rate (2026–2036): XX%

DelveInsight's ‘Chlamydia Epidemiology Forecast 2036’ report delivers an in-depth understanding of the chlamydia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chlamydia Understanding and Diagnosis Algorithm

Chlamydia Overview and Diagnosis

Chlamydia trachomatis is a common sexually transmitted bacterial infection (STI) that often remains asymptomatic, especially in women, but can affect the urogenital tract and cause complications like pelvic inflammatory disease and infertility. In men, symptoms may include urethral discharge, burning urination, testicular pain (epididymitis), or mild urethritis, while women may experience abnormal vaginal discharge, burning urination, intermenstrual or post-coital bleeding, and pelvic pain. If left untreated in either gender, it can lead to serious reproductive complications such as infertility, ectopic pregnancy in women, and epididymitis or reactive arthritis in men.

Further details are provided in the report.....

Chlamydia Diagnosis

Diagnosis is mainly done using nucleic acid amplification tests (NAATs), which are the most sensitive and specific tests for detecting chlamydia DNA or RNA from urine samples or genital swabs (cervical, vaginal, or urethral). Rectal or throat swabs may also be used depending on exposure history. Screening is recommended for sexually active individuals at high risk, especially women under 25 years and those with multiple partners or a history of STIs.

Further details are provided in the report.....

Chlamydia Epidemiology

Key Findings from Chlamydia Epidemiological Analysis and Forecast 

• Urogenital chlamydia infections are the most frequently reported bacterial infections in the United States.

• Chlamydia is the most commonly diagnosed sexually transmitted infection in the United Kingdom, with infection rates being higher in women than in men.

• Age plays a significant role in determining risk, with women aged 15 to 24 experiencing the highest rates of infection. 

• In 2025, Germany recorded the highest number of diagnosed incident chlamydia cases among the EU4 and UK countries. According to DelveInsight’s projections, this number is expected to increase by 2036.

• In the United States, chlamydia was more Incident among females than males. In 2025, approximately 70% of the reported cases were in females, while around 30% were in males. DelveInsight predicts that these numbers will continue to rise by 2036.

• As per secondary analysis, despite a slowdown in the increase of chlamydia notifications in 2023, it remains the most frequently reported bacterial STI in Europe. In 2023, more than 230 000 cases were reported across EU/EEA countries, representing an increase of 13% since 2014. The infection continues to disproportionately affect young people, with the highest rates among women aged 20–24. 

• As per secondary analysis, approximately 169,000 new chlamydia cases were reported across all ages in 2024, reflecting a 13% decrease from 2023, when around 194,000 cases were recorded.

Scope of the Report

• The report covers a segment of a descriptive overview of chlamydia, explaining their causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Chlamydia Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting

• 11-year Forecast 

• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of chlamydia? What will be the growth opportunities across the 7MM concerning the patient population with chlamydia?

• What is the historical and forecasted chlamydia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.

• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.